Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.
Feature|Articles|October 28, 2026
The Next Biopharma Revolution: Quantum Computing
Author(s)Sam Anwar
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Advertisement
Advertisement
Since the current administration’s executive order to accelerate quantum innovation announced in June, we’ve seen massive breakthroughs from ETH Zurich’s “vibrating” quantum memory chip for managing complex algorithms to NVIDIA demonstrating an AI error-correction model that can suppress quantum data noise.
Related to this article
Merck KGaA, Darmstadt, Germany, agrees to acquire Silence Therapeutics for roughly $1.3 billion, gaining a siRNA asset, divesiran.
Dave Maraldo, Ph.D., president of manufacturing at Merck, explains how flexible capacity, earlier input from manufacturing in R&D, and digital tools are helping the organization keep up with a faster, more varied portfolio.
Deborah Waterhouse is leaving ViiV Healthcare to become CEO and managing director of CSL.
METiS TechBio enters a collaboration with Eli Lilly to develop next-generation, tissue-specific lipid nanoparticle delivery technologies using METiS’s AI-driven lipid discovery platform.
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.
Advertisement
Advertisement